Researchers from the Wistar Institute have engineered a synthetic DNA vaccine able to provide potent immunity against the emerging Mayaro virus in mice models.
Browsing: Basic > Pre-clinical Trials
A biomimetic, micromotor vaccine formulation has shown promising results in immunizing against Staphylococcus aureus in mouse models.
An mRNA-based vaccine has been demonstrated to protect against Powassan virus in mice, in addition to also conferring protection against the more distantly related Langat virus.
Researchers have successfully used monoclonal antibodies to protect animal models from Candida infections for the first time, demonstrating their potential for treating this fungal disease.
Researchers from the University of Zurich have discovered that thanatin, a compound produced naturally by the spined soldier bug, could target Gram-negative bacteria by preventing formation of the bacteria’s outer membrane – an unprecedented mechanism.
Small molecules that block bacterial toxin formation have shown promise against Gram-positive bacteria in mouse models.
Experimental HIV-1 vaccine regimen is safe and elicits a robust immune response according to results of a Phase I/IIa clinical trial.
Recent technological advancements have allowed organoids to become a viable research tool for a wide range of development and disease models. Here, we look at some of the research that’s been done in infectious diseases and delve into what the future of organoids might look like.
A high-fiber diet can boost the immune response and increase survival in mice infected with influenza virus, according to new research.
Two genetically-modified broadly-neutralizing antibodies have been demonstrated to elicit long-term protection against an HIV-like virus in rhesus macaques, with a Phase I clinical trial now underway.